Impetigo Clinical Trial
Official title:
Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
The purpose of this study is to document the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with bacterial infections, including impetigo, folliculitis, and minor soft tissue infections including secondarily infected eczema presumed to be caused by methicillin resistant Staph aureus. Male and female patients ages 9 months to 98 years will be recruited from a university based dermatology clinic. Upon enrollment, wound cultures will be collected, and then subjects will apply topical retapamulin twice daily for five days. The primary endpoint will be resolution of methicillin-resistant Staphylococcus aureus (MRSA) infection based on clinical presentation and physical exam, as well as bacteriological efficacy based on culture results. It is anticipated that approximately 75 patients will be enrolled, with expectation that approximately 50 of these patients will have MRSA infections.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00884728 -
Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory
|
N/A | |
| Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
| Completed |
NCT01153828 -
EU PV for Retapamulin-Prescribing
|
N/A | |
| Recruiting |
NCT05345093 -
Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, Impetigo and Folliculitis
|
N/A | |
| Active, not recruiting |
NCT05226260 -
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
|
N/A | |
| Terminated |
NCT00986856 -
Fucidin® Cream in the Treatment of Impetigo
|
Phase 4 | |
| Completed |
NCT01397461 -
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
|
Phase 3 | |
| Recruiting |
NCT02090764 -
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
|
Phase 3 | |
| Completed |
NCT02775617 -
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
|
Phase 4 | |
| Not yet recruiting |
NCT01611909 -
Citriodiol® and Impetigo
|
Phase 2/Phase 3 | |
| Completed |
NCT03177993 -
Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
|
N/A | |
| Completed |
NCT03429595 -
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
|
Phase 2 | |
| Completed |
NCT04287777 -
Safety and Efficacy of Mupirocin Gel in Children With Impetigo
|
Phase 3 | |
| Completed |
NCT00626795 -
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
|
Phase 2 | |
| Completed |
NCT00758862 -
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
|
Phase 2 | |
| Recruiting |
NCT01943136 -
The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial
|
Phase 1 | |
| Completed |
NCT01670032 -
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
|
Phase 2/Phase 3 | |
| Completed |
NCT01171326 -
Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
|
Phase 2 | |
| Completed |
NCT01367314 -
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
|
Phase 2 | |
| Completed |
NCT00852540 -
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
|
Phase 3 |